Welcome to our dedicated page for Innovative Indus SEC filings (Ticker: IIPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innovative Industrial Properties, Inc. filings document the disclosure record of a Maryland REIT that owns specialized industrial properties and life science real estate through an UPREIT structure. Periodic and current reports cover operating results, supplemental financial information, rental revenue, portfolio leasing activity, tenant-related matters, and the economics of its cannabis and life science property portfolios.
The company’s SEC filings also describe secured term loans, promissory notes, unsecured senior notes, preferred stock, share repurchase authorization, dividend and distribution disclosures, and material definitive agreements. Proxy materials cover annual meeting matters, board composition, executive compensation, stockholder voting items and governance practices.
Innovative Industrial Properties, Inc. completed the initial closing of a previously announced preferred equity investment in IQHQ REIT on September 30, 2025 through its subsidiary IIP Life Science Investments LLC. The subsidiary purchased Series G-1 Preferred Stock at $1,000 per share for a total investment of approximately $5.0 million and received a warrant exercisable for common equity units equal to 1.5% of fully diluted IQHQ Holdings, LP. On the same date, IIP Life Science funded a committed loan of $100.0 million to IQHQ OP, bringing total funded amounts under the related reserve credit facility to $400.0 million. The Company also obtained a contractual right of first offer on certain IQHQ real estate assets. The report lists related agreements and a press release as exhibits and is signed by CFO David Smith.
Innovative Industrial Properties, through its operating partnership IIP OP, agreed to a multi-part strategic investment in IQHQ entities consisting of up to $170.0 million to purchase cumulative redeemable preferred stock and a $100.0 million committed lender role in a revolving credit facility. The preferred shares carry a 10.0% cash dividend and an initial 5.0% PIK dividend, with PIK step-ups and certain penalty mechanics tied to Trigger Events.
The transaction includes equity warrants (initial 1.5% and subsequent 3.5% coverage at $0.01 exercise price), a contractual right of first offer on IQHQ real estate sales, the right to appoint a voting director (intended to be CEO Paul Smithers), and customary closing conditions, timing limits and default/penalty provisions.
IIPR’s Q2-25 results show weakening fundamentals amid tenant stress. Rental revenue fell 21% YoY to $62.9 m as PharmaCann and other operators struggled, driving net income down 38% to $26.0 m and diluted EPS to $0.86 (vs $1.44).
Cash flow from operations remained positive at $102.7 m but slipped 24% YoY; cash on hand dropped to $99.7 m after funding $22.9 m of investments, repurchasing $20.1 m of common stock and paying $108.7 m in common dividends ($1.90/sh each quarter). Dividends now exceed cumulative earnings, pushing “dividends in excess of earnings” to –$264 m.
Balance-sheet leverage is modest (liabilities $425 m vs equity $1.88 b), yet the $291 m 5.5% notes maturing May 2026 loom large. Management admits current liquidity is insufficient and intends to refinance, assuming access to capital markets.
Tenant concentration remains high: top five operators generated 49% of rental revenue; PharmaCann defaulted in March, nullifying rent concessions, while two leases shifted to sales-type accounting with cash payments booked as deposits. An impairment of $3.5 m was recorded in Q1 and one California asset was sold for $1.8 m at book value.
The company issued 559 k Series A preferred shares via its ATM for $13.2 m and increased preferred outstanding to 1.56 m shares; early bond repayments of $8.8 m trimmed debt. Multiple securities-law class actions remain pending.